Keywords: Hospital-treated infections, Drug market growth, Emerging therapies, Decision Resources

Major constraints in the hospital-treated infections drug market include generic erosion

Article | 06 December 2012

The hospital-treated infections (HTI) drug market, the loss of patent protection for key branded products - notably Pfizer’s ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in